Allogeneic Second-generation CD19-CAR T Cells therapy(Bambino Gesu Hospital And Research Institute)

N/A

Report date: 2023/11/10 20:06:06

Base Information

Drug NameAllogeneic Second-generation CD19-CAR T Cells therapy(Bambino Gesu Hospital And Research Institute)

Drug Alias NameAllogeneic CD19-directed chimeric antigen receptor T-cells therapy(Bambino Gesu Hospital And Research Institute)CD19-CAR_Lenti_ALLOallogeneic, CD19-directed Chimeric Antigen Receptor T (alloCAR-T) cells therapy(Bambino Gesu Hospital And Research Institute)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulators

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryItaly

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBambino Gesu Hospital And Research Institute

China Registration ClassN/A

Develop Information

Active CompaniesBambino Gesu Hospital And Research Institute

Inactive CompaniesN/A

Active IndicationsPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A